摘要
目的研究乳腺癌肿瘤组织中TopoⅡα浓度和临床资料多因素之间的关系,分析其分布规律及观察含蒽环类药物联合化疗疗效。方法通过分析78例乳腺癌患者组织中TopoⅡαm RNA的表达水平,并与患者的年龄、月经状态、病理分型、临床分期、转移情况、ER、PR、Her-2及含蒽环类药物联合化疗疗效之间的关系进行分析。结果在不同年龄、月经状态、病理分型、临床分期中TopoⅡα的表达差异无统计学意义,Topo IIα阳性组中位TTF 16周高于阴性组的12周(P<0.05),同时腋窝淋巴结转移率75.61%高于阴性组51.35%(P<0.05),含蒽环类药物化疗疗效有效率58.54%高于阴性组的40.54%(P<0.05)。结论 TopoⅡαm RNA的表达水平可以作为评介乳腺癌预后的独立因素,并可作为遴选化疗药物,进行个体化治疗的指标。
Objective The relationship between multiple Topo Ⅱα concentration and clinical research in breast cancer tissue, analysis of the distribution and observation of anthracycline containing chemotherapy efficacy. Methods Through the analysis of expression level of 78 cases of breast cancer tissues of Topo Ⅱα mRNA, and with the patient＇s age, menopausal status, pathological type, clinical stage, metastasis, ER, PR, Her- 2 and anthracycline containing chemotherapy curative effect analysis of the relationship between. Results In a different age, menopausal status, pathological type, clinical staging Topo Ⅱα no expression difference, Topo Ⅱα positive median TTF 16 weeks higher than 12 weeks negative group （P 〈0.05）, while axillary lymph nodes transfer rate 75.61% higher than the negative group 51.35% （P 〈0.05）, anthracycline containing chemotherapy drugs efficiency 58.54% higher than negative group （40.54%）（P 〈0.05）. Conclusion The Topo Ⅱα mRNA expression levels can be used as independent prognostic factors in Breast cancer, and also can serve as the selection of chemotherapeutic drugs and individual treatment indicators.
出处
《当代医学》
2015年第30期66-67,共2页
Contemporary Medicine
